PRINCETON, N.J.--(BUSINESS WIRE)--Nov. 10, 2016--
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration
company focused on advanced wound and burn care, announced today that
Stephen T. Wills, the Company’s Executive Chairman and Interim Principal
Executive Officer, will present at the Canaccord Genuity Medical
Technologies & Diagnostics Forum on Thursday, November 17th at 10:30
a.m. Eastern time. The conference is being held at the Westin Grand
Central Hotel in New York City.
To listen to the presentation, investors may visit the investor
relations section of Derma Sciences’ website at www.dermasciences.com.
An archived audio of the presentation will also be available on Derma
Sciences’ website for 90 days.
About Derma Sciences, Inc.
Derma Sciences is a tissue regeneration company focused on
patent-protected and proprietary advanced wound and burn care
treatments. The Company’s lead products include TCC-EZ®, a gold-standard
total contact casting system for diabetic foot ulcers, and its
MEDIHONEY® product line, the leading brand of honey-based dressings for
the management of wounds and burns. It is also engaged in the
development and commercialization of novel proprietary regenerative
products derived from placental/birth tissues for use in a broad range
of clinical applications including the treatment of complex chronic
wounds, acute wounds and localized areas of injury or inflammation, in
addition to filling soft tissue defects or voids. These products are
used in orthopedic, spinal and ocular surgical procedures, among others.
The Company also offers a full product line of traditional dressings.
For more information, please visit www.dermasciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110006447/en/
Source: Derma Sciences, Inc.
Derma Sciences, Inc.
Executive Chairman and Interim Principal
Sutton Golodetz, 212-838-3777